CA1319628C - Fusion proteins - Google Patents

Fusion proteins

Info

Publication number: CA1319628C
Authority: CA; Canada
Prior art keywords: vector; virus; epitope; fusion protein; antigenic epitope
Prior art date: 1987-02-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA000534146A

Other languages

English (en)

French (fr)

Inventor

Peter Edmund Highfield

Berwyn Ewart Clarke

Anthony Robin Carroll

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Wellcome Foundation Ltd

Original Assignee

Wellcome Foundation Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-02-10

Filing date

1987-04-08

Publication date

1993-06-29

1987-04-08 Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd

1993-06-29 Application granted granted Critical

1993-06-29 Publication of CA1319628C publication Critical patent/CA1319628C/en

2010-06-29 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

108020001507 fusion proteins Proteins 0.000 title claims abstract description 49
102000037865 fusion proteins Human genes 0.000 title claims abstract description 48
239000013598 vector Substances 0.000 claims abstract description 50
101710132601 Capsid protein Proteins 0.000 claims abstract description 49
230000000890 antigenic effect Effects 0.000 claims abstract description 46
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 14
229960005486 vaccine Drugs 0.000 claims abstract description 13
108091028043 Nucleic acid sequence Proteins 0.000 claims abstract 15
238000000034 method Methods 0.000 claims description 43
210000004027 cell Anatomy 0.000 claims description 39
241000710198 Foot-and-mouth disease virus Species 0.000 claims description 27
241000700605 Viruses Species 0.000 claims description 20
241000894006 Bacteria Species 0.000 claims description 12
239000013612 plasmid Substances 0.000 claims description 11
239000000427 antigen Substances 0.000 claims description 10
102000036639 antigens Human genes 0.000 claims description 10
108091007433 antigens Proteins 0.000 claims description 10
241000700618 Vaccinia virus Species 0.000 claims description 9
125000000539 amino acid group Chemical group 0.000 claims description 8
210000004962 mammalian cell Anatomy 0.000 claims description 7
239000013603 viral vector Substances 0.000 claims description 7
230000003612 virological effect Effects 0.000 claims description 7
241000588724 Escherichia coli Species 0.000 claims description 5
241000701076 Macacine alphaherpesvirus 1 Species 0.000 claims description 4
239000013605 shuttle vector Substances 0.000 claims description 4
239000003085 diluting agent Substances 0.000 claims description 3
238000002360 preparation method Methods 0.000 claims description 3
240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
241000991587 Enterovirus C Species 0.000 claims 7
241000430519 Human rhinovirus sp. Species 0.000 claims 7
241000223960 Plasmodium falciparum Species 0.000 claims 7
241000712461 unidentified influenza virus Species 0.000 claims 7
241000700721 Hepatitis B virus Species 0.000 claims 4
238000012258 culturing Methods 0.000 claims 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims 1
108020004414 DNA Proteins 0.000 description 29
108090000623 proteins and genes Proteins 0.000 description 27
102000004169 proteins and genes Human genes 0.000 description 15
150000002500 ions Chemical class 0.000 description 12
206010046865 Vaccinia virus infection Diseases 0.000 description 6
208000007089 vaccinia Diseases 0.000 description 6
150000001413 amino acids Chemical class 0.000 description 5
239000012634 fragment Substances 0.000 description 5
101150043276 Lon gene Proteins 0.000 description 4
238000002965 ELISA Methods 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
238000010276 construction Methods 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
239000000463 material Substances 0.000 description 3
229960004452 methionine Drugs 0.000 description 3
230000000813 microbial effect Effects 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
241000700199 Cavia porcellus Species 0.000 description 2
108020005202 Viral DNA Proteins 0.000 description 2
239000002253 acid Substances 0.000 description 2
102000005936 beta-Galactosidase Human genes 0.000 description 2
108010005774 beta-Galactosidase Proteins 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
238000010367 cloning Methods 0.000 description 2
230000006801 homologous recombination Effects 0.000 description 2
238000002744 homologous recombination Methods 0.000 description 2
239000013600 plasmid vector Substances 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
230000010076 replication Effects 0.000 description 2
235000012976 tarts Nutrition 0.000 description 2
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
101100194816 Caenorhabditis elegans rig-3 gene Proteins 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
102000004594 DNA Polymerase I Human genes 0.000 description 1
108010017826 DNA Polymerase I Proteins 0.000 description 1
102000052510 DNA-Binding Proteins Human genes 0.000 description 1
108700020911 DNA-Binding Proteins Proteins 0.000 description 1
101100009046 Dictyostelium discoideum hemE gene Proteins 0.000 description 1
241000588914 Enterobacter Species 0.000 description 1
241001131785 Escherichia coli HB101 Species 0.000 description 1
241001669573 Galeorhinus galeus Species 0.000 description 1
101001064282 Homo sapiens Platelet-activating factor acetylhydrolase IB subunit beta Proteins 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
108091036060 Linker DNA Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
101150106956 Oxtr gene Proteins 0.000 description 1
102100030655 Platelet-activating factor acetylhydrolase IB subunit beta Human genes 0.000 description 1
102000007327 Protamines Human genes 0.000 description 1
108010007568 Protamines Proteins 0.000 description 1
101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
108091081024 Start codon Proteins 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
101150003725 TK gene Proteins 0.000 description 1
101150064238 TR gene Proteins 0.000 description 1
101150106192 Urod gene Proteins 0.000 description 1
QXAITBQSYVNQDR-UHFFFAOYSA-N amitraz Chemical compound C=1C=C(C)C=C(C)C=1N=CN(C)C=NC1=CC=C(C)C=C1C QXAITBQSYVNQDR-UHFFFAOYSA-N 0.000 description 1
238000010171 animal model Methods 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
230000027455 binding Effects 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000007771 core particle Substances 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000003599 detergent Substances 0.000 description 1
230000029087 digestion Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000004927 fusion Effects 0.000 description 1
238000012215 gene cloning Methods 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000002372 labelling Methods 0.000 description 1
238000013507 mapping Methods 0.000 description 1
AYOOGWWGECJQPI-NSHDSACASA-N n-[(1s)-1-(5-fluoropyrimidin-2-yl)ethyl]-3-(3-propan-2-yloxy-1h-pyrazol-5-yl)imidazo[4,5-b]pyridin-5-amine Chemical compound N1C(OC(C)C)=CC(N2C3=NC(N[C@@H](C)C=4N=CC(F)=CN=4)=CC=C3N=C2)=N1 AYOOGWWGECJQPI-NSHDSACASA-N 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
229940048914 protamine Drugs 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
239000013014 purified material Substances 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000005199 ultracentrifugation Methods 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1

Classifications

- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

CA000534146A 1987-02-10 1987-04-08 Fusion proteins Expired - Fee Related CA1319628C (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US1294887A	1987-02-10	1987-02-10
US012,948		1987-02-10

Publications (1)

Publication Number	Publication Date
CA1319628C true CA1319628C (en)	1993-06-29

Family

ID=21757520

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000534146A Expired - Fee Related CA1319628C (en)	1987-02-10	1987-04-08	Fusion proteins

Country Status (4)

Country	Link
JP (1)	JPS63196299A (ja)
AU (2)	AU596154B2 (ja)
CA (1)	CA1319628C (ja)
NZ (1)	NZ219516A (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ235315A (en) *	1989-09-19	1991-09-25	Wellcome Found	Chimaeric hepadnavirus core antigen proteins and their construction
SE468050C (sv) *	1991-03-15	1998-04-27	Pharmacia & Upjohn Ab	Rekombinant derivat av human faktor VIII
RU2212899C2 (ru) *	1991-09-13	2003-09-27	Чирон Корпорейшн	Hcv иммунореактивные полипептидные композиции
DK0996717T3 (da) *	1997-08-05	2006-04-10	Vlaams Interuniv Inst Biotech	Immunbeskyttende influenzaantigen og anvendelse deraf til vaccination
US7731972B1 (en)	2000-02-04	2010-06-08	Vlaams Interuniversitair Instituut Voor Biotechnologie	Immunoprotective influenza antigen and its use in vaccination
EP1841785A2 (en)	2005-01-19	2007-10-10	Vaxinnate Corporation	Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
EP2476432B1 (en)	2006-03-07	2015-08-19	Vaxinnate Corporation	Compositions that include hemagglutinin, methods of making and methods of use thereof
ES2594102T3 (es)	2008-04-18	2016-12-15	Vaxinnate Corporation	Mutantes por deleción de la flagelina y métodos para su uso
BRPI0924068A2 (pt) *	2008-12-25	2016-07-26	Chemo Sero Therapeut Res Inst	vacina recombinante contra coriza infecciosa das aves e processo para preparação da mesma
US8932598B2 (en)	2012-08-28	2015-01-13	Vaxinnate Corporation	Fusion proteins and methods of use
WO2017032303A1 (zh) *	2015-08-25	2017-03-02	厦门大学	一种用于展示目的多肽的多肽载体及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZW18282A1 (en) *	1981-08-31	1983-03-23	Genentech Inc	Preparation of polypeptides in vertebrate cell culture
AU572108B2 (en) *	1983-01-19	1988-05-05	Genentech Inc.	Human tpa production using vectors coding for dhfr protein
ATE70308T1 (de) *	1984-09-12	1991-12-15	Chiron Corp	Hybridpartikel-immunogene.
JPS6274295A (ja) *	1985-09-25	1987-04-06	チロン　コ−ポレイシヨン	ハイブリツド粒状免疫原
NZ219515A (en) *	1987-02-10	1989-09-27	Wellcome Found	Fusion proteins comprising influenza virus ha and a nonnatural antigenic epitope

1987
- 1987-03-05 NZ NZ219516A patent/NZ219516A/xx unknown
- 1987-03-06 AU AU69792/87A patent/AU596154B2/en not_active Ceased
- 1987-03-07 JP JP62052829A patent/JPS63196299A/ja active Pending
- 1987-04-08 CA CA000534146A patent/CA1319628C/en not_active Expired - Fee Related
1990
- 1990-02-08 AU AU49273/90A patent/AU642859B2/en not_active Ceased

Also Published As

Publication number	Publication date
AU6979287A (en)	1988-08-11
AU596154B2 (en)	1990-04-26
JPS63196299A (ja)	1988-08-15
AU642859B2 (en)	1993-11-04
AU4927390A (en)	1990-08-09
NZ219516A (en)	1991-02-26

Legal Events

Date	Code	Title	Description
1996-01-01	MKLA	Lapsed

Publication	Publication Date	Title
CA1319628C (en)	1993-06-29	Fusion proteins
CA1319629C (en)	1993-06-29	Fusion proteins
Cheng et al.	1986	Hepatitis B virus large surface protein is not secreted but is immunogenic when selectively expressed by recombinant vaccinia virus
Kieny et al.	1984	Expression of rabies virus glycoprotein from a recombinant vaccinia virus
Efimov et al.	1995	Bacteriophage T4 as a surface display vector
AU562548B2 (en)	1987-06-11	Virus with recombinant surface proteins
EP2360174B1 (en)	2014-04-09	HBV core antigen particles with multiple immunogenic components attached via peptide ligands
Imamura et al.	1987	Expression of hepatitis B virus middle and large surface antigen genes in Saccharomyces cerevisiae
Funk et al.	2007	Avian hepatitis B viruses: molecular and cellular biology, phylogenesis, and host tropism
Valenzuela et al.	1985	Synthesis and assembly in yeast of hepatitis B surface antigen particles containing the polyalbumin receptor
JPH0690769A (ja)	1994-04-05	バキュロウイルス発現系
Borisova et al.	1996	Spatial structure and insertion capacity of immunodominant region of hepatitis B core antigen
RU2454462C2 (ru)	2012-06-27	Частицы с расщепленным ядром, предназначенные для презентации чужеродных молекул, прежде всего для применения в вакцинах, и способ их получения
Yu et al.	2005	The specific delivery of proteins to human liver cells by engineered bio‐nanocapsules
Vogel et al.	2005	Quaternary structure is critical for protein display on capsid‐like particles (CLPs): efficient generation of hepatitis B virus CLPs presenting monomeric but not dimeric and tetrameric fluorescent proteins
Cheng et al.	1987	Selective synthesis and secretion of particles composed of the hepatitis B virus middle surface protein directed by a recombinant vaccinia virus: induction of antibodies to pre-S and S epitopes
Karayiannis et al.	1993	Partial control of hepatitis delta virus superinfection by immunisation of woodchucks (Marmota monax) with hepatitis delta antigen expressed by a recombinant vaccinia or baculovirus
Cooper et al.	2005	Recombinant viral capsids as an efficient vehicle of oligonucleotide delivery into cells
Vijaya et al.	1988	Transport to the cell surface of a peptide sequence attached to the truncated C terminus of an N-terminally anchored integral membrane protein
WO2023125739A1 (zh)	2023-07-06	一种病毒样颗粒及其制备方法和应用
JPH02501114A (ja)	1990-04-19	蛋白質合成用発現ベクター及びかゝるベクター構成に使用するプラスミドレプリコン及び配列カセット
von Weizsäcker et al.	1995	Identification of two separable modules in the duck hepatitis B virus core protein
Srinivasan et al.	1995	Targeting vaccinia virus-expressed secretory beta subunit of human chorionic gonadotropin to the cell surface induces antibodies
JPS63500637A (ja)	1988-03-10	組換えウイルス
AU647040B2 (en)	1994-03-17	A recombinant birth control vaccine